Allogene Therapeutics Experiences Steep Loss in Recent Trading Session

Trending News 🌧️

Allogene Therapeutics ($NASDAQ:ALLO), Inc. is a clinical-stage biopharmaceutical company. The company focuses on the development of allogeneic CAR T cell therapies for cancer. The recent sell-off was sparked by a couple of factors. This dilutes existing shareholders and puts downward pressure on the stock price. While the company said that the deaths were unrelated to the treatment, it’s understandable that investors would be skittish about investing in a company whose main product has just been involved in two patient deaths. The company’s main product is in clinical trials and has already been associated with two patient deaths.

In addition, the company is selling new shares, which will dilute existing shareholders. Given the risks, investors should tread carefully with this stock.

Stock Price

Allogene Therapeutics, a clinical-stage biopharmaceutical company, saw a steep loss in its stock price during Friday’s trading session. At the time of writing, news sentiment towards the company was mostly positive. However, the stock opened at $9.7 and closed at $9.3, down by 1.9% from its previous closing price of $9.5. This is a significant drop for the company, and investors will be closely watching to see how it fares in the coming days.

VI Analysis

Allogene Therapeutics is a company that develops therapies for cancer. Its fundamentals reflect its long term potential. Based on the VI Risk Rating, Allogene Therapeutics is a medium risk investment in terms of financial and business aspects.

The VI App has detected 3 risk warnings in the balance sheet, cash flow statement, and financial journal. Register on vi.app to check it out.

VI Peers

Allogene Therapeutics Inc is a clinical-stage biopharmaceutical company, engaged in the development of allogeneic CAR T cell therapies for the treatment of cancer. Allogene Therapeutics Inc’s competitors are Arvinas Inc, Nascent Biotech Inc, JW (Cayman) Therapeutics Co Ltd.

– Arvinas Inc ($NASDAQ:ARVN)

Arvinas Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing proteolysis-targeting chimeras (PROTACs) to degrade and control proteins that drive disease. Arvinas has a market cap of 2.29B as of 2022 and a Return on Equity of -32.37%. The company’s lead product candidate, ARV-110, is in clinical development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Arvinas is also developing ARV-471 for the treatment of HER2-positive breast cancer and ARV-825 for the treatment of urothelial cancer.

– Nascent Biotech Inc ($OTCPK:NBIO)

Nascent Biotech Inc is a clinical-stage biopharmaceutical company with a focus on developing monoclonal antibodies to treat various cancers. The company’s market cap is 26.93M as of 2022 and its ROE is 55.87%. Nascent Biotech Inc is a relatively small company, but it has shown impressive growth potential. The company’s focus on developing monoclonal antibodies to treat cancer is a promising area of research that could lead to breakthrough treatments for this devastating disease.

– JW (Cayman) Therapeutics Co Ltd ($SEHK:02126)

JW (Cayman) Therapeutics Co Ltd is a clinical stage biopharmaceutical company focused on developing and commercializing novel cancer immunotherapies. The company’s lead product candidate, JTX-2011, is a first-in-class, off-the-shelf, multi-antigen targeted T cell therapy being evaluated in a Phase 1/2 clinical trial for the treatment of solid tumors. JW (Cayman) Therapeutics Co Ltd has a market cap of 1.32B as of 2022, a Return on Equity of -19.61%.

Summary

Allogene Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic CAR T therapies for cancer. Allogene’s product candidates are based on its proprietary allogeneic CAR T platform, which uses healthy donor cells to create CAR T cells that can be administered to patients without the need for a pre-treatment regimen. This approach has the potential to reduce the risk of serious adverse events associated with current CAR T therapies, as well as to expand the number of patients who can benefit from this treatment modality.

Allogene has entered into strategic collaborations with several leading companies in the CAR T space, including Kite Pharma, Inc. , Servier, Cellectis S.A., and Pfizer Inc. These collaborations provide Allogene with access to important CAR T technologies and expertise, as well as to potential commercialization and manufacturing resources. Allogene is headquartered in South San Francisco, California.